Evotec AG has received a $3.1 million milestone payment through its research alliance with Boehringer Ingelheim. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology program. Dr. Werner Lanthaler, chief executive officer of Evotec, commented, “We are particularly pleased about achieving this milestone in the oncology program, as the alliance was only expanded to this therapeutic area in late 2009. We are very proud of the high v...